Engineered patient T cells using Chimeric Antigen Receptors (CARs) are a great invention from the last decade, eradicating tumors and providing durable cancer remissions. However, first generation CAR-Ts require complex logistics and labor-intensive processing, which takes 1-2 months to bring the therapy to the patient. In addition, it is costly. CellPoint has developed an unconventional CAR-T manufacturing and supply strategy based on fully closed and automated manufacturing at the point-of-care.
Want to know more? https://www.cellpoint.bio/